• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Theranostics >The Prognostic Value of 18F-FDG PET/CT for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization (TACE)
【2h】

The Prognostic Value of 18F-FDG PET/CT for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization (TACE)

机译：18F-FDG PET / CT对经肝动脉化疗栓塞（TACE）治疗的肝细胞癌的预后价值

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

18F-Fluoro-deoxyglucose (FDG) PET/CT can be used to monitor the biological behavior of hepatocellular carcinoma (HCC). Baseline PET/CT has prognostic value in HCC patients, but there is litter knowledge of the PET/CT changes after treatment. We evaluated 27 HCC patients treated with transarterial chemoembolization (TACE) from June 2011 to July 2012, and we investigated the prognostic value of PET/CT. Patients were followed up with regular clinical and laboratory examinations and contrast-enhanced spiral computed tomography (CT). Furthermore, PET/CT assessments were collected and analyzed before (range 1~15 d) and after the first month of TACE (range, 27~45d). We tested the prognostic value of the tumor standardized uptake value (TSUV) and normal liver SUV(LSUV) according to the VOI (volume of interest). The SUVs were used to assess the relationship between the treatment response and survival. To assess their prognostic value, we evaluated the areas under the receiver operating characteristic (ROC) curves of different SUVs for predicting survival. Finally, the median overall survival (OS) and time to progression (TTP) for 27 patients were 15.4 months (95%CI, 3.3-27.5 months) and 11.4 months (95%CI, 6.7-16.1 months), respectively. The ΔTSUVmax%, based on the VOI, had the highest discriminative prognostic value and the cutoff PET/CT response was 0.1 with a sensitivity of 100% and a specificity of 95.2%. The OS was significantly better in the PET/CT response group than in the PET/CT non-response group (p=0.025). In conclusion, an early interim PET/CT after TACE may have prognostic value for HCC patients treated with TACE, and the ΔTSUVmax% may help in determining the HCCs viability in patients with high baseline and follow-up18F-FDG uptake.
机译： 18 F-氟脱氧葡萄糖（FDG）PET / CT可用于监测肝细胞癌（HCC）的生物学行为。基线PET / CT在肝癌患者中具有预后价值，但是对治疗后PET / CT的变化了解甚少。我们评估了2011年6月至2012年7月接受经动脉化疗栓塞（TACE）治疗的27例HCC患者，并研究了PET / CT的预后价值。对患者进行定期的临床和实验室检查以及对比增强的螺旋CT（CT）。此外，在TACE的第一个月（27〜45d）之前（范围1〜15 d）和PET / CT评估被收集和分析。我们根据VOI（目标体积）测试了肿瘤标准化摄取值（TSUV）和正常肝脏SUV（LSUV）的预后价值。 SUV被用于评估治疗反应与生存之间的关系。为了评估其预后价值，我们评估了不同SUV的接收器工作特征（ROC）曲线下的面积，以预测生存率。最后，27位患者的中位总生存期（OS）和进展时间（TTP）分别为15.4个月（95％CI，3.3-27.5个月）和11.4个月（95％CI，6.7-16.1个月）。基于VOI的ΔTSUVmax％具有最高的判别性预后值，PET / CT截止反应值为0.1，敏感性为100％，特异性为95.2％。 PET / CT反应组的OS明显优于PET / CT无反应组（p = 0.025）。综上所述，TACE治疗后早期PET / CT对TACE治疗的肝癌患者可能具有预后价值，而ΔTSUVmax％可能有助于确定基线和随访较高的肝癌患者的生存力 18 F-FDG吸收。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号